The acquired product line includes Enlon (edrophonium chloride injection, USP) 10mg/ml, 15ml vial, Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection 5ml ampule and Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection, 15ml multi-dose vial.
Bioniche purchased the rights and certain assets related to the Enlon product line from Baxter, which discontinued Enlon in February 2008. Bioniche anticipates launching all three codes of Enlon in October 2008.
Steve Thornton, CEO of Bioniche Pharma, said: “We are pleased to reintroduce these products, providing health care professionals with access to additional options.”